8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Jan 12, 2026·SEC
SI-BONE, Inc.(SIBN)Earnings, Financials & Key Ratios
SIBN•NASDAQ
$17.30
Price updated Jul 7, 2026
AboutSI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.Show more
- Revenue$201M+20.2%
- EBITDA-$20M+36.5%
- Net Income-$19M+38.8%
- EPS (Diluted)-0.44+41.3%
- Gross Margin79.57%+0.7%
- EBITDA Margin-9.76%+47.1%
- Operating Margin-11.11%+47.3%
- Net Margin-9.41%+49.1%
- ROE-10.98%+40.3%
SIBN Price & Volume
SI-BONE, Inc. (SIBN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Deficits Challenge Revenue Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Decelerating
Profitability:Negative
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Persistent Operating Margin Deficit
Key Thesis Takeaways
- SI-BONE maintains a strong competitive moat with consistent 79.8% gross margins, yet the company struggles to achieve operating leverage as revenue growth decelerated to 11.2% in 2026Q1.
- While the balance sheet remains robust with a 9.99 current ratio and minimal debt, the reliance on stock-based compensation exceeding $6 million per quarter masks underlying cash burn.
- Investors should monitor whether the company can successfully decouple its heavy sales force investment from revenue growth to reach sustainable profitability.
Verdict Logic
while the company maintains a healthy balance sheet with a 9.99 current ratio, the persistent negative operating margin of -9.7% and decelerating revenue growth warrant a cautious wait-and-see approach.
SIBN Growth Metrics
SI-BONE, Inc. (SIBN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years17.18%
5 Years22.32%
3 Years23.6%
TTM16.77%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM37.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.39%
Return on Capital
10 Years-31.99%
5 Years-24.13%
3 Years-18.41%
Last Year-10.72%
SIBN Recent Earnings
SI-BONE, Inc. (SIBN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.10+41.2%
$0.17
Rev
$53M+2.8%
$51M
Q1 2026
Feb 23, 2026Metric
Actual
Est
EPS
$0.04+69.2%
$0.13
Rev
$56M+1.7%
$55M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.11+31.3%
$0.16
Rev
$49M-13.5%
$56M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.14+26.3%
$0.19
Rev
$49M+4.2%
$47M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.10vs $0.17+41.2% | $53Mvs $51M+2.8% |
| Q1 2026 | Feb 23, 2026 | $0.04vs $0.13+69.2% | $56Mvs $55M+1.7% |
| Q4 2025 | Nov 10, 2025 | $0.11vs $0.16+31.3% | $49Mvs $56M-13.5% |
| Q3 2025 | Aug 4, 2025 | $0.14vs $0.19+26.3% | $49Mvs $47M+4.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for SI-BONE, Inc. (SIBN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.30 | $767.24M | -39.32 | 20.19% | -9.41% | -10.98% | — | |
| $0.42 | $58.84M | 13.98 | 14.21% | 1.5% | 3.68% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $78.83 | $10.63B | 20.11 | 16.65% | 18.92% | 13.04% | — | |
| $218.72 | $3.61B | 25.11 | 11.33% | 8.42% | 16.74% | — |
Compare SIBN vs Peers
SI-BONE, Inc. (SIBN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SIBN SEC Filings & Documents
SI-BONE, Inc. (SIBN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SIBN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SIBN Frequently Asked Questions
SI-BONE, Inc. (SIBN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is SI-BONE, Inc.'s revenue?
SI-BONE, Inc. (SIBN) reported $206.2M in revenue for fiscal year 2025. This represents a 321% increase from $49.0M in 2013.
How fast is SI-BONE, Inc. growing?
SI-BONE, Inc. (SIBN) grew revenue by 20.2% over the past year. This is strong growth.
Is SIBN profitable?
SI-BONE, Inc. (SIBN) reported a net loss of $16.7M for fiscal year 2025.
Dividend & Returns
What is SIBN's return on equity?
SI-BONE, Inc. (SIBN) has a return on equity (ROE) of -11.0%. Negative ROE indicates the company is unprofitable.
What is SI-BONE, Inc.'s free cash flow?
SI-BONE, Inc. (SIBN) had negative free cash flow of $5.5M in fiscal year 2025, likely due to heavy capital investments.